Aribio Surpasses 1,100 Patients Dosed in Global Phase 3 Trial of AR1001

More than 1,100 patients have now completed dosing in the global Phase 3 clinical trial of AR1001, an oral Alzheimer’s treatment being developed by Aribio. On April 28, the company announced that this achievement means it has reached the target number of patients specified in the clinical protocol, securing both statistical validity and data reliability requirements.

The trial is currently being conducted in 13 countries. Participation in the one-year Open-Label Extension study, which follows the main trial, has exceeded 95%. As a result, over 1,000 patients continue to receive ongoing medication. According to the company, the high participation rate reflects the perceived effectiveness and acceptability of the drug among patients and their caregivers. In fact, additional dosing requests have reportedly been made even among patients who have completed two years of treatment.

The global Phase 3 trial of AR1001 (POLARIS-AD) is scheduled to finish dosing a total of 1,535 patients by June 2026. Aribio plans to announce topline data around September and subsequently submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).

As the trial approaches its final stage, AR1001’s strategy of utilizing a “multimodal mechanism” is drawing increasing attention from both academia and the market. In particular, following the publication of the 2026 Cochrane Review, skepticism has grown regarding the clinical efficacy of anti-amyloid antibody therapies, with more voices pointing out the limitations of single-mechanism treatments. This is due to the fact that, while existing therapies have shown effectiveness in removing amyloid, cognitive decline has persisted and side effects such as brain edema and brain hemorrhage (ARIA) have emerged as significant issues.

From the early stages of development, Aribio adopted a multimodal mechanism strategy to address the complex causes of Alzheimer’s disease. AR1001, a small-molecule compound, is highly permeable across the blood-brain barrier (BBB) and features a mode of action distinct from antibody therapies, which mainly target extracellular plaque removal.

This drug simultaneously achieves multiple effects: it inhibits the overexpression of the protein (PDE5) that breaks down the brain neurotransmitter cGMP, thereby improving cerebral blood flow, activating neuroprotective genes, enhancing synaptic plasticity, and suppressing the phosphorylation of toxic tau proteins. Moreover, despite its potent PDE5 inhibitory action, it does not cause side effects such as visual disturbances or muscle pain, supporting its long-term safety profile.

Sharon Sha, Director of the Stanford Neurosciences Institute and global Phase 3 principal investigator, commented, “Unlike conventional anti-amyloid therapies, AR1001 is a new PDE5 inhibitor and multimodal agent capable of addressing the complex pathology of Alzheimer’s disease simultaneously.”

Fred Kim, Head of Aribio’s U.S. branch, said, “In a context where anti-amyloid–focused strategies are being re-examined, the multimodal approach of AR1001 is naturally receiving increased attention. If meaningful results are confirmed in the Phase 3 trial, there is a strong possibility that it could become a first-line treatment.”

Meanwhile, Aribio is pursuing a merger with Kosdaq-listed company Solux, with the merger scheduled for August 11, 2026.

This content was produced with the assistance of AI translation services.